Personalised Medicine by using an Advanced Point-of-Care Tool for Stratified Treatment in High Risk Cardiovascular Patients (PoCCardio)

使用先进的护理点工具对高危心血管患者进行分层治疗的个性化医疗 (PoCCardio)

• 批准号: 10107153
• 金额: $ 102.52万
• 依托单位: LABMAN AUTOMATION LIMITED
• 依托单位国家: 英国
• 项目类别: EU-Funded
• 财政年份: 2023
• 资助国家: 英国
• 起止时间: 2023 至 无数据
• 项目状态: 未结题
• 来源: https://gtr.ukri.org/projects?ref=10107153
• 关键词: Personalised; Medicine; using; Advanced; Point

Cardiovascular diseases (CVDs) are the leading cause of death worldwide. Besides established risk factors such as elevated blood pressure, blood glucose or lipid levels, circulating proteomic as well as genetic markers allow further stratification of patients. While some of these markers can be measured routinely in low-threshold healthcare institutions, others require access to highly specialized and costly laboratory environment which usually can be found only within larger tertiary settings. The aim of this project is to advance and tailor a point-of-care (PoC) tool, which was recently developed within the framework of HORIZON 2020. Using cutting-edge lab-on-a-chip (LoC) and microfluidic technology, the tool will be further developed to measure qualified biomarkers and polymorphisms from finger prick blood, in order to help identify, classify and monitor cardiovascular patients at high risk. The clinical validation of these biomarkers and the PoC tool will then be performed in a prospective, randomised multinational trial which will include only existing and approved pharmaceuticals. Based on their specific pattern of qualified biomarkers, patients will be assigned either to standard pharmacological treatment, or tailored intensified treatment. Data derived from the clinical validation study will constitute a rich source for complex AIpowered computational analysis to explore potential predictors for primary and secondary outcome parameters. The trial will further provide the scientific foundation to support regulatory authorities in regard to approval of companion diagnostics, and recommendations for the prescription of drugs, respectively. Overall, this project aims to improve care and treatment efficacy in CVD patients through an advanced biomarker-driven PoC-based personalised medicine. To achieve these aims, a well-balanced consortium of five academic research partners and two SMEs has been brought together.

心血管疾病(CVD)是世界范围内主要的死亡原因。除了已确定的危险因素，如高血压、血糖或血脂水平升高，循环蛋白质组和遗传标记允许进一步对患者进行分层。虽然其中一些标记物可以在低门槛医疗机构中进行常规测量，但其他标记物需要进入高度专业化和昂贵的实验室环境，而这种环境通常只有在较大的第三级环境中才能找到。该项目的目的是推进和定制一个护理点(PoC)工具，该工具是最近在Horizon 2020框架内开发的。利用尖端的芯片实验室(LoC)和微流控技术，该工具将进一步开发，从手指刺血中测量合格的生物标记物和多态性，以帮助识别、分类和监测高危心血管患者。这些生物标记物和PoC工具的临床验证将在一项前瞻性的随机多国试验中进行，该试验将只包括现有和批准的药物。根据患者特定的合格生物标志物模式，患者将被分配到标准药物治疗或量身定制的强化治疗。来自临床验证研究的数据将构成复杂的人工智能计算分析的丰富来源，以探索主要和次要结果参数的潜在预测因素。该试验将进一步提供科学基础，以支持监管当局分别批准伴随诊断和建议开药。总体而言，该项目旨在通过先进的生物标记物驱动的基于PoC的个性化药物来提高CVD患者的护理和治疗效果。为了实现这些目标，一个由五个学术研究伙伴和两个中小企业组成的平衡的财团已经聚集在一起。